IQVIA (NYSE:IQV) Reaches New 12-Month Low – Here’s Why

IQVIA Holdings Inc. (NYSE:IQV) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $169.37 and last traded at $176.28, with a volume of 2234715 shares changing hands. The stock had previously closed at $177.39.

Analyst Upgrades and Downgrades

A number of analysts recently commented on IQV shares. Robert W. Baird lowered their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Finally, Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

The stock has a fifty day moving average of $192.73 and a 200-day moving average of $205.61. The firm has a market capitalization of $31.08 billion, a P/E ratio of 23.50, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Hedge Funds Weigh In On IQVIA

Large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after purchasing an additional 712,958 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after buying an additional 77,981 shares during the last quarter. Invesco Ltd. grew its stake in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock valued at $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after buying an additional 59,426 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.